The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk

Cancer

Volumn 119, Issue 13, 2013, Pages 2477-2485

  Angstadt, Andrea Y ^a   Berg, Arthur ^a   Zhu, Junjia ^a   Miller, Paige ^b   Hartman, Terryl J ^c   Lesko, Samuel M ^d   Muscat, Joshua E ^a   Lazarus, Philip ^a   Gallagher, Carla J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d Northeast Regional Cancer Institute   (United States)

Author keywords

colorectal cancer risk; copy number variation; phase II detoxification; UGT2B17; UGT2B28

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CAUCASIAN; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DEMOGRAPHY; DRUG DETOXIFICATION; FEMALE; GENE; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM CANCER; RISK REDUCTION; SEX DIFFERENCE; UGT2B17 GENE; UGT2B28 GENE;

ADULT; AGED; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MEAT; MEAT PRODUCTS; METABOLIC DETOXICATION, PHASE II; MIDDLE AGED; PENNSYLVANIA; QUESTIONNAIRES; RECTAL NEOPLASMS; RISK FACTORS; SEX FACTORS;

EID: 84879109687     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28009     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Bacolod MD, Barany F,. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol. 2011; 18: 3694-3700.
3. Ferrari P, Jenab M, Norat T, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2007; 121: 2065-2072.
4. Gallagher CJ, Muscat JE, Hicks AN, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 823-828.
5. Nagar S, Remmel RP,. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene. 2006; 25: 1659-1672.
6. McCarroll SA, Hadnott TN, Perry GH, et al. International HapMap Consortium. Common deletion polymorphisms in the human genome. Nat Genet. 2006; 38: 86-92.
7. Ménard V, Eap O, Harvey M, Guillemette C, Lévesque E,. Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism. Hum Mutat. 2009; 30: 1310-1319.
8. Jakobsson J, Ekström L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006; 91: 687-693.
9. Swanson C, Mellström D, Lorentzon M, et al. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab. 2007; 92: 4878-4882.
10. Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P,. Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos. 2010; 38: 2204-2209.
11. Lévesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Belanger A,. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001; 40: 3869-3881.
12. Joshi N, Johnson LL, Wei WQ, et al. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006; 66: 6851-6860.
13. Yoshida T, Kobayashi T, Itoda M, et al. Clinical omics analysis of colorectal cancer incorporating copy number aberrations and gene expression data. Cancer Inform. 2010; 9: 147-161.
14. Setlur SR, Chen CX, Hossain RR, et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19: 229-239.
15. Nadeau G, Bellemare J, Audet-Walsh E, et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab. 2011; 96: E1550-E1557.
16. Alpert HA, Prokup I, Lesko SM,. Colorectal cancer incidence and mortality in Northeastern Pennsylvania. J Registry Manag. 2007; 34: 99.
17. Bailey RL, Miller PE, Mitchell DC, et al. Dietary screening tool identifies nutritional risk in older adults. Am J Clin Nutr. 2009; 90: 177-183.
18. Wang Y, Beydoun MA,. Meat consumption is associated with obesity and central obesity among US adults. Int J Obes (Lond). 2009; 33: 621-628.
19. World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: WHO; 2000.
20. Thompson FE, Subar AF, Brown CC, et al. Cognitive research enhances accuracy of food frequency questionnaire reports: results of an experimental validation study. J Am Diet Assoc. 2002; 102: 212-225.
21. Friday J, Bowman S,. MyPyramid Equivalents Database for USDA Survey Food Codes, 1994-2002. Version 1.0. Beltsville, MD: USDA Agricultural Research Service; 2006. http://www.ars.usda.gov/Services/docs.htm?docid=8503#pyramid.
22. Greenland S, Rothman K,. Introduction to stratified analysis. In:, Rothman K, Greenland S, Lash T, eds. Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
23. Willett WC, Howe GR, Kushi LH,. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr. 1997; 65 (4 suppl): 1220S-1228S.
24. Biesheuvel CJ, Vergouwe Y, Steyerberg EW, Grobbee DE, Moons KG,. Polytomous logistic regression analysis could be applied more often in diagnostic research. J Clin Epidemiol. 2008; 61: 125-134.
25. Miller PE, Lazarus P, Lesko SM, et al. Meat-related compounds and colorectal cancer risk by anatomical subsite. Nutr Cancer. 2013; 65: 202-226.
26. Skjelbred CF, Saebø M, Hjartåker A, et al. Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer. 2007; 7: 228.
27. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P,. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006; 34: 943-949.
28. Sneitz N, Krishnan K, Covey DF, Finel M,. Glucuronidation of the steroid enantiomers ent-17beta-estradiol, ent-androsterone and ent-etiocholanolone by the human UDP-glucuronosyltransferases. J Steroid Biochem Mol Biol. 2011; 127: 282-288.
29. Sten T, Kurkela M, Kuuranne T, Leinonen A, Finel M,. UDP- glucuronosyltransferases in conjugation of 5alpha- and 5beta-androstane steroids. Drug Metab Dispos. 2009; 37: 2221-2227.
30. Turgeon D, Carrier JS, Chouinard S, Bélanger A,. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos. 2003; 31: 670-676.
31. Karypidis AH, Olsson M, Andersson SO, Rane A, Ekström L,. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2008; 8: 147-151.
32. Park J, Chen L, Ratnashinge L, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1473-1478.
33. Ding K, Kullo IJ,. Geographic differences in allele frequencies of susceptibility SNPs for cardiovascular disease. BMC Med Genet. 2011; 12: 55.
34. Dubé C, Rostom A, Lewin G, et al. U.S. Preventive Services Task Force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007; 146: 365-375.
35. Din FV, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010; 59: 1670-1679.
36. Kurzawa-Zegota M, Najafzadeh M, Baumgartner A, Anderson D,. The protective effect of the flavonoids on food-mutagen-induced DNA damage in peripheral blood lymphocytes from colon cancer patients. Food Chem Toxicol. 2012; 50: 124-129.
37. Kyle JA, Sharp L, Little J, Duthie GG, McNeill G,. Dietary flavonoid intake and colorectal cancer: a case-control study. Br J Nutr. 2010; 103: 429-436.
38. Kuehl GE, Lampe JW, Potter JD, Bigler J,. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005; 33: 1027-1035.
39. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T,. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos. 2008; 36: 1461-1464.